Supplements

Best Practices: Biomarkers and Treatment Selection in the Management of Advanced NSCLC

2022 Midyear Review: Non–Small-Cell Lung Cancer

First-Line Treatment of Metastatic Non-small cell Lung Cancer (NSCLC)

First-Line OPDIVO® (nivolumab) in Combination with Chemotherapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma

Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy
Lung cancer is the second-most common type of cancer in the United States, including approximately 235,000 new cases each year, 84% of which are non–small-cell lung cancer (NSCLC). Read More ›

Best Practices in Multiple Myeloma: Improving Adherence to Optimize Patient Outcomes

First-Line OPDIVO® (nivolumab) in Combination with Chemotherapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma

2021 Year in Review - Multiple Myeloma

February 2022 Clinical Trials to Clinical Practice

2021 Year in Review: Advances in Dual Immunotherapy Cancer Treatments
Dual immunotherapy for cancer has been one of the most successful modes of treatment researched and developed in recent years, with many new studies having been completed this past year. Read More ›

Page 1 of 6


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: